Brokerages Set $10.50 Target Price for Check Cap Ltd (NASDAQ:CHEK)

Check Cap Ltd (NASDAQ:CHEK) has earned a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and one has given a strong buy rating to the company.

Brokers have set a twelve-month consensus price target of $10.50 for the company and are forecasting that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 104 out of 256 based on the ratings given to its competitors.

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Beyondspring in a report on Wednesday. Zacks Investment Research raised HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a report on Friday, May 17th.



Shares of CHEK stock traded up $0.06 during mid-day trading on Friday, reaching $2.22. The stock had a trading volume of 111,605 shares. The business has a fifty day moving average of $2.24. The company has a market cap of $3.55 million and a price-to-earnings ratio of -0.85. Check Cap has a 1-year low of $1.62 and a 1-year high of $4.50.

Check Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Monday, May 13th. The medical research company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. Sell-side analysts forecast that Check Cap will post -1.69 earnings per share for the current year.

Check Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Read More: Support Level

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.